Welcome to NEBA

NorthEast Bioanalytical Laboratories, LLC (NEBA), is a global GLP contract analytical laboratory specializing in bioanalytical mass spectrometry and immunochemistry for the pharmaceutical, biotechnology, and animal healthcare industries. Our goal is to provide our clients with an array of services, and to provide those services in a very efficient and personalized manner.

NEBA, an FDA-audited facility, has assisted in the development of several approved drugs and has experience working with clients to support clinical trials for new drug application (NDA) submissions.


I have worked with a number of companies (large and small) over the years and NEBA is by far the most responsive. In an industry where a vast majority of businesses establish practices that remain rigid, NEBA works with the client to provide the most efficient and cost effective approach to getting the job done. The integrity of the scientific staff is refreshing as well as their willingness to provide scientific input and high quality data. They truly go the extra mile to make the collaborations successful and I will continue to enjoy very productive interactions with them in the future.

-  Tom Stephen, Ph.D.,
CGI Pharmaceuticals, Inc.

My experience with NEBA has been a very good one. We received all the results and reports in desired format and without any problems. Our experience with NEBA personnel were highly professional and cordial in nature. They have provided us with high quality work that has been timely and well presented. They have provided valuable insight with pharmacokinetics and analysis of the data (especially with the preclinical studies). I plan to continue using their services in the future and would highly recommend them to prospective clients.

-  David Goldman, Ph.D.,
Pharmaceuticals International, Inc.

The studies ranged from method validation and stability studies, cross-validation of other external labs, support for Investigator Sponsored Studies, Clinical Phase I to Phase IV studies (including pivotal BE studies). The last major study was a pivotal bioequivalence study, where samples from a cross-over study with about 100 volunteers were to be analyzed within a very short time frame. This study - and all other studies - were done according to a very high quality and reporting standard and with a high responsiveness. We have audited the Lab in 2004 by our BHC GLP QAU and in 2006 by a BHC GLP trained bioanalytical expert, in both cases without major findings.

-  Bernhard Beckermann, Ph.D.,
Bayer Schering AG, Germany